
|Videos|August 2, 2014
Curing and Managing Late Toxicities in Testicular Cancer
Author(s)Lawrence H. Einhorn, MD
Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, discusses curing and managing late toxicities in testicular cancer.
Advertisement
Clinical Pearls
Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, Giant of Cancer Care: Genitourinary Cancer, discusses curing and managing late toxicities in testicular cancer.
- Drug resistance can be overcome by giving five times the dosage of cytolytic agents. This can be done safely because patients are given back their hematopoietic stem cells by peripheral blood stem-cell transplant.
- Research is being conducted to improve the cure rate of testicular cancer.
- Many young patients who are cured experience complications such as cardiovascular disease and peripheral neuropathy later.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Breast Cancer Test Using Proteomic Profiling and AI Demonstrates High Performance
5










































